Monthly Migraine

In children and teenagers, treatment with zonisamide was associated with a significant reduction in the number of monthly migraine days, particularly after at least 2 months of use, preliminary data show.

Treatment with atogepant 60mg once daily significantly reduced monthly migraine days at 12 weeks compared with oral rimegepant 75mg every other day, according to research published in Cephalalgia.

Treatment with atogepant at 30 mg and 60 mg reduced mean monthly migraine days over 12 weeks compared with placebo, while showing good safety and tolerability profiles, according to research published in the Lancet Neurology.

DENVER — Treatment with Vyepti was associated with a sustained reduction in the frequency of episodic and chronic migraines over 6 months, researchers reported at the American Headache Society annual scientific meeting.

Oral atogepant once per day effectively decreased the number of migraine and headache days over 12 weeks, according to findings from the phase 3 ADVANCE trial that were published in The New England Journal of Medicine.